KR20200092946A - 결정질 리나글립틴 중간체 및 리나글립틴 제조 공정 - Google Patents
결정질 리나글립틴 중간체 및 리나글립틴 제조 공정 Download PDFInfo
- Publication number
- KR20200092946A KR20200092946A KR1020207012196A KR20207012196A KR20200092946A KR 20200092946 A KR20200092946 A KR 20200092946A KR 1020207012196 A KR1020207012196 A KR 1020207012196A KR 20207012196 A KR20207012196 A KR 20207012196A KR 20200092946 A KR20200092946 A KR 20200092946A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- linagliptin
- crystalline form
- reaction
- linagliptin intermediate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 title claims abstract description 49
- 229960002397 linagliptin Drugs 0.000 title claims abstract description 48
- 238000004519 manufacturing process Methods 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims 6
- 239000012296 anti-solvent Substances 0.000 claims 2
- 239000000376 reactant Substances 0.000 claims 1
- 239000000523 sample Substances 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 238000000634 powder X-ray diffraction Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000011521 glass Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000001144 powder X-ray diffraction data Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- -1 4-methyl-2-quinazolinyl Chemical group 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 2
- FAIAJSOSTNJZCI-UHFFFAOYSA-N purine-2,6-dione Chemical compound O=C1NC(=O)C2=NC=NC2=N1 FAIAJSOSTNJZCI-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229940049667 tradjenta Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201741034292 | 2017-09-27 | ||
| IN201741034292 | 2017-09-27 | ||
| PCT/IB2018/057484 WO2019064214A1 (en) | 2017-09-27 | 2018-09-27 | INTERMEDIATE OF CRYSTALLINE LINAGLIPTIN AND PROCESS FOR THE PREPARATION OF LINAGLIPTIN |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20200092946A true KR20200092946A (ko) | 2020-08-04 |
Family
ID=65903063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207012196A Ceased KR20200092946A (ko) | 2017-09-27 | 2018-09-27 | 결정질 리나글립틴 중간체 및 리나글립틴 제조 공정 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11040974B2 (enExample) |
| JP (1) | JP2020535193A (enExample) |
| KR (1) | KR20200092946A (enExample) |
| CN (1) | CN111511743A (enExample) |
| AU (1) | AU2018343236A1 (enExample) |
| BR (1) | BR112020005964A2 (enExample) |
| CA (1) | CA3076980A1 (enExample) |
| MX (1) | MX2020004050A (enExample) |
| RU (1) | RU2020114890A (enExample) |
| WO (1) | WO2019064214A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110684026A (zh) * | 2019-10-24 | 2020-01-14 | 扬子江药业集团上海海尼药业有限公司 | 一种利格列汀的工业化制备方法 |
| CN110872292B (zh) * | 2019-11-30 | 2022-01-25 | 江苏君若药业有限公司 | 一条合成糖尿病药物利拉利汀的路线 |
| EP4349837A1 (en) | 2022-10-05 | 2024-04-10 | Zaklady Farmaceutyczne "Polpharma" S.A. | A pharmaceutical intermediate |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| BRPI0711558A2 (pt) | 2006-05-04 | 2011-11-08 | Boeringer Ingelheim Internat Gmbh | polimorfos |
| IN2013MU02055A (enExample) * | 2013-06-18 | 2015-07-03 | Cadila Healthcare Ltd | |
| WO2015011609A1 (en) * | 2013-07-23 | 2015-01-29 | Ranbaxy Laboratories Limited | Process for the preparation of linagliptin and an intermediate thereof |
-
2018
- 2018-09-27 WO PCT/IB2018/057484 patent/WO2019064214A1/en not_active Ceased
- 2018-09-27 MX MX2020004050A patent/MX2020004050A/es unknown
- 2018-09-27 CA CA3076980A patent/CA3076980A1/en active Pending
- 2018-09-27 JP JP2020517938A patent/JP2020535193A/ja active Pending
- 2018-09-27 KR KR1020207012196A patent/KR20200092946A/ko not_active Ceased
- 2018-09-27 CN CN201880076836.6A patent/CN111511743A/zh active Pending
- 2018-09-27 AU AU2018343236A patent/AU2018343236A1/en not_active Abandoned
- 2018-09-27 RU RU2020114890A patent/RU2020114890A/ru unknown
- 2018-09-27 BR BR112020005964-1A patent/BR112020005964A2/pt not_active Application Discontinuation
-
2020
- 2020-03-27 US US16/832,067 patent/US11040974B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3076980A1 (en) | 2019-04-04 |
| US11040974B2 (en) | 2021-06-22 |
| AU2018343236A1 (en) | 2020-05-14 |
| MX2020004050A (es) | 2020-11-06 |
| RU2020114890A (ru) | 2021-10-27 |
| JP2020535193A (ja) | 2020-12-03 |
| US20200354363A1 (en) | 2020-11-12 |
| WO2019064214A1 (en) | 2019-04-04 |
| BR112020005964A2 (pt) | 2020-10-06 |
| CN111511743A (zh) | 2020-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI585088B (zh) | 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物 | |
| EP2985277A1 (en) | Dipyrromethene crystal and method for manufacturing same | |
| KR102810009B1 (ko) | 고체 형태의 fgfr 억제제 화합물 및 그 제조방법 | |
| JP2019518776A (ja) | Ｅｇｆｒ阻害剤としてのアニリンピリミジン化合物の結晶 | |
| WO2017125097A1 (en) | Crystalline forms of (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4- yl)pyrazol-l-yl]propanenitrile salts and preparation thereof | |
| US11040974B2 (en) | Crystalline linagliptin intermediate and process for preparation of linagliptin | |
| CZ2014502A3 (cs) | Nová forma sofosbuviru a způsob její přípravy | |
| US20090054424A1 (en) | Optically active pyridine derivative and a medicament containing the same | |
| US20240217977A1 (en) | Diazepanone-fused pyrimidine compounds, compositions and medicinal applications thereof | |
| CN118434730A (zh) | 一种glp-1受体激动剂的可药用盐、结晶形式及其制备方法 | |
| EP3322709B1 (en) | Crystalline forms of (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile salts and preparation thereof | |
| EP3919479B1 (en) | Compound having benzo seven-membered ring structure, preparation method therefor, and use thereof | |
| EP3321267A1 (en) | Crystalline forms of 2-[1-ethylsulfonyl-3-[7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile salts and preparation thereof | |
| EP4446317A1 (en) | Salt of 3,4-dihydroisoquinoline compound and use thereof | |
| CN114685520B (zh) | 三并环化合物及其药物组合物和应用 | |
| CN113227096A (zh) | 1,2,3-三氮唑并[1,5-a]吡嗪类衍生物的晶型及其制备方法 | |
| EP1950206A1 (en) | Benzoxazocines and their use as monoamine-reuptake inhibitors | |
| US11827614B2 (en) | Synthetic pathway to belzutifan and crystalline phases of synthetic intermediates | |
| MX2011003529A (es) | Compuestos de tiazolil-pirazolopirimidina como intermediarios sinteticos y procesos sinteticos relacionados. | |
| US12084454B2 (en) | Process for preparing BTK inhibitors | |
| KR20200092945A (ko) | 레날리도마이드의 결정형 | |
| EP4644374A1 (en) | Naphthylamide compound, and preparation method therefor and use thereof | |
| CN112830919B (zh) | 苯并哌啶衍生物可药用盐及其制备方法 | |
| US20230034132A1 (en) | Crystal form as inhibitor of acc1 and acc2, and preparation method therefor and use thereof | |
| EP4592286A1 (en) | Macrocyclic nitrogen-containing crown ether compound and use thereof as protein kinase inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20200427 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210901 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20231006 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20240102 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20231006 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |